Navigation Links
BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza
Date:9/21/2009

BIRMINGHAM, Ala., Sept. 21 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza.

"We are very excited to continue working with the U.S. government to advance the development of peramivir," said Jon P. Stonehouse, President and Chief Executive Officer, BioCryst Pharmaceuticals. "Peramivir is being developed with HHS to treat seriously ill and hospitalized patients, with the goal of saving lives. This contract modification supports peramivir's Phase 3 clinical development with the aim of gaining U.S. regulatory approval."

"There are currently no anti-viral drugs approved to treat seriously ill patients with influenza who need hospital care," said Dr. William P. Sheridan, Chief Medical Officer at BioCryst. "BioCryst is committed to working with the U.S. government to advance the development of peramivir to address unmet medical needs for an intravenous treatment for influenza. We intend to initiate our Phase 3 studies as soon as possible."

This contract modification brings the total award from HHS for the development of peramivir to $179.9 million and extends the contract term by 12 months to five years. BioCryst was originally awarded a $102.6 million, four-year contract from the HHS to develop peramivir for the treatment of influenza in January 2007. Under the original contract, peramivir was advanced through Phase 2 and the initial steps of Phase 3 development.

Phase 3 Development of peramivir

BioC
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst to Present at UBS Global Life Sciences Conference
2. BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
3. BioCryst Executives to Present at Two Investor Conferences
4. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
5. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
6. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
7. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
8. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
9. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... even mild asthma among young inner-city children appears to be ... after diagnosis is a wise move as a hedge against ... according to a study from the Johns Hopkins Childrens Center. ... months after diagnosis, but six months may be too long ...
... Hopkins have evidence to explain why the supposedly natural act ... for life-threatening heart failure. , In a study ... (AHA) annual Scientific Sessions in Orlando, Fla., the Hopkins team ... pumping function to assess minute changes in the hearts of ...
... to do more to erase racial disparities, study suggests , ... pressure among heart failure patients vary widely by race and ... the Medical University of South Carolina, Mt. Pleasant, noted that ... but experts know little about actual rates of treatment and ...
... at AHA, including one from the Framingham Heart Study,link PAT ... ... ORLANDO, Fla., Nov. 4 Itamar Medical announced,confirmation of ... confirmation of PAT technology, Itamar Medical will now,promote clinical use ...
... increase the rate of coronary reperfusion (restoring blood flow ... the quality of care these patients received, according to ... coincide with its release at the American Heart Associations ... November 28 print issue of JAMA. , ST-segment ...
... Six Percent of Patients Discontinued Combination Therapy ... 4 New data released today,showed that ... proprietary extended-release niacin, Niaspan(R), and,simvastatin met its ... cholesterol minus HDL), while demonstrating improvements,on other ...
Cached Medicine News:Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2Health News:Statewide program helps improve quality of care for heart attack 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 3Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 4Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 5
(Date:12/24/2014)...   The issue: ... confirmed it contains two undeclared amphetamine-like drug substances that ... Empire Health Distribution of Terrebonne, Quebec ... Canada .  Jetfuel Superburn is promoted ... increased energy. What consumers should do ...
(Date:12/24/2014)... -- Kinex Pharmaceuticals announced today that the first patient ... Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, ... inhibitory activity against a broad panel of brain tumor ... (T98G), the most widely used chemotherapy for the treatment ... model, KX2-361 consistently clears brain tumors after 4 weeks ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... Israel, December 20, 2011 During its meeting ... Governors of the Israel-U.S. Binational Industrial Research and Development ... new projects between Israeli and American companies. In addition to ... funding, boosting the total value of all projects to $22 ...
... a medical device company based in Worcester, MA developing ... Company,s $6 M Series B Preferred Stock offering closed ... been catalyzed by our technical progress and recent additions ... Scientific Advisory Board," explained Arthur Combs, Grove,s CEO. ...
Cached Medicine Technology:BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 2BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 3Grove Instruments Inc. Closes $6 M Series B Financing 2Grove Instruments Inc. Closes $6 M Series B Financing 3
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
... Aaron manufactures two groups of flexible ... sterile and non-sterile in three different sizes ... flexible shaft portion of the light). These ... additional light is needed., ,The second ...
... toggle switches at off (center position) , ... pulses/10 s) , Tetanus: 50 Hz (50 pulses/s) ... (4 pulses/2 s); repeat (4 pulses/2 s; repeats ... 0-70 mA(HI range) 0-6.0mA (LO range) , Stimulus ...
... Operation: , Standby: A standby switch maintains power ... Twitch: 1 s (1 pulse/s) , Tetanus: ... pulses/2 s) , Output Current: Adjustable from 0-70 ... pulses (200-us duration) , Indicators: Battery LED (green) ...
Medicine Products: